In vitro and in vivo biological characterization of the anti-proliferative potential of a cyclic trinuclear organotin(iv) complex

Abstract Circulating osteogenic precursor (COP) cells constitute a recently discovered population of circulating progenitor cells with the capacity to form not only bone but other mesenchymal tissues. A small but growing body of literature explores these cells, but with a great deal of disagreement and contradiction within it, mainly whether these cells are from mesenchymal or hematopoietic origin. This session will discuss the origins and biological characterization of these cells, including the identification strategies used to isolate these cells from the peripheral blood. It also examines the available knowledge on the in vitro and in vivo behaviour of these cells in plastic adherence, differentiation capacity, proliferation, and cellular homing. We will also review the profound and exciting implications for future use of COP cells in clinical practice, particularly in comparison with other types of stem cells.

Download Full-text

Programming the anti-tumor immune response in vitro and its application to stop the growth of tumor cells and prolonging the lifespan of mice with carcinoma in vivo

ZHurnal «Patologicheskaia fiziologiia i eksperimental`naia terapiia» ◽

10.25557/igpp.2017.4.8525 ◽

2017 ◽

pp. 67-73

Author(s):

С.В. Калиш ◽

С.В. Лямина ◽

А.А. Раецкая ◽

О.П. Буданова ◽

И.Ю. Малышев

Keyword(s):

Immune Response ◽

Tumor Growth ◽

Tumor Cells ◽

The Body ◽

Ehrlich Carcinoma ◽

Ec Cells ◽

Growth Of Tumor ◽

Immune Response In Vitro

Цель - представить доказательства правомерности гипотезы, что комбинированный пул репрограммированных in vitro макрофагов и лимфоцитов будет эффективно ограничивать пролиферацию опухолевых клеток in vitro , а при введении в организм будет существенно ограничивать развитие опухоли in vivo . Методика. Размножение опухолевых клеток инициировали in vitro путем добавления клеток карциномы Эрлиха (КЭ) в среду культивирования RPMI-1640. Развитие асцитной опухоли in vivo воспроизводили путем внутрибрюшной инъекции клеток КЭ мышам. Результаты. Установлено, что M3 макрофаги вместе с антиген-репрограммированными лимфоцитами оказывают выраженный противоопухолевый эффект и in vitro, и in vivo , который был существеннее противоопухолевого эффекта цисплатина. Заключение. Факты, свидетельствующие, что М3 макрофаги в сочетании с in vitro антиген-репрограммированными лимфоцитами значительно подавляют рост опухоли in vivo , делают перспективным разработку клинической версии биотехнологии ограничения роста опухоли путем предварительного программирования противоопухолевого иммунного ответа «в пробирке». Aim. To test a hypothesis that a combined pool of in vitro reprogrammed macrophages and lymphocytes will effectively limit growth of tumor cells in vitro , and injections of these cells into the body will considerably limit development of a tumor in vivo . Methods. Tumor growth was initiated in vitro by addition of Ehrlich carcinoma (EC) cells to the RPMI-1640 cell culture medium and in vivo by intraperitoneal injection of EC cells into mice. Results. M3 macrophages in combination with antigen-reprogrammed lymphocytes exerted a pronounced antitumor effect both in vitro and in vivo, which was superior to the effect of cisplatin. Conclusion. M3 macrophages in combination with in vitro antigen-reprogrammed lymphocytes significantly inhibited the tumor growth in vivo . This fact justifies development of a clinical version of the tumor growth restricting biotechnology using pre-programming of the antitumor immune response in vitro .

Download Full-text

RNAi-mediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo

Oncogene ◽

10.1038/onc.2008.163 ◽

2008 ◽

Vol 27 (40) ◽

pp. 5315-5325 ◽

Cited By ~ 54

Author(s):

A Bessard ◽

C Frémin ◽

F Ezan ◽

A Fautrel ◽

L Gailhouste ◽

...

Keyword(s):

Tumor Cells ◽

Growth Of Tumor

Download Full-text

Abstract LB-363: Characterization of in vitro and in vivo models generated from disseminated tumor cells of patients without manifest metastasis

10.1158/1538-7445.am2018-lb-363 ◽

2018 ◽

Author(s):

Christian Werno ◽

Kathrin Weidele ◽

Steffi Treitschke ◽

Catherine Botteron ◽

Sebastian Scheitler ◽

...

Keyword(s):

Tumor Cells ◽

Disseminated Tumor Cells ◽

In Vivo Models

Download Full-text

Biological characterization of purified macrophage-derived neutrophil chemotactic factor

Mediators of Inflammation ◽

10.1155/s0962935195000421 ◽

1995 ◽

Vol 4 (4) ◽

pp. 263-269 ◽

Cited By ~ 9

Author(s):

M. Dias-Baruffi ◽

M. C. Roque-Barreira ◽

F. Q. Cunha ◽

S. H. Ferreira

Keyword(s):

Neutrophil Migration ◽

Chemotactic Activity ◽

Chemotactic Factor ◽

Biological Characterization ◽

Important Mediator ◽

Neutrophil Chemotactic Factor ◽

Chemotactic Gradient

We have recently described the purification of a 54 kDa acidic protein, identified as macrophage-derived neutrophil chemotactic factor (MNCF). This protein causesin vitrochemotaxis as well asin vivoneutrophil migration even in animals treated with dexamethasone. Thisin vivochemotactic activity of MNCF in animals pretreated with dexamethasone is an uncommon characteristic which discriminates MNCF from known chemotactic cytokines. MNCF is released in the supernatant by macrophage monolayers stimulated with lipopolysaccharide (LPS). In the present study, we describe some biological characteristics of homogenous purified MNCF. When assayedin vitro, MNCF gave a bell-shaped dose–response curve. Thisin vitroactivity was shown to be caused by haptotaxis. Unlike N-formyl-methionylleucyl- phenylalanine (FMLP) or interleukin 8 (IL-8), the chemotactic activity of MNCFin vivoandin vitro, was inhibited by preincubation with D-galactose but not with D-mannose. In contrast with IL-8, MNCF did not bind to heparin and antiserum against IL-8 was ineffective in inhibiting its chemotactic activity. These data indicate that MNCF induces neutrophil migration through a carbohydrate recognition property, but by a mechanism different from that of the known chemokines. It is suggested that MNCF may be an important mediator in the recruitment of neutrophils via the formation of a substrate bound chemotactic gradient (haptotaxis) in the inflamed tissues.

Download Full-text

In vitro and in vivo application of the GILUPI cell collector system for the isolation and characterization of circulating tumor cells (CTCs) in lung cancer patients

10.1183/13993003.congress-2015.pa526 ◽

2015 ◽

Author(s):

Michael Fleichhacker ◽

Hubertus Rolke ◽

Clemens Oerding ◽

Gerit Theil ◽

Bettina Wollschläger ◽

...

Keyword(s):

Lung Cancer ◽

Cancer Patients ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Lung Cancer Patients ◽

Collector System ◽

Isolation And Characterization

Download Full-text

Molecular and Functional Characterization of Circulating Tumor Cells: From Discovery to Clinical Application

Clinical Chemistry ◽

10.1373/clinchem.2019.303586 ◽

2019 ◽

Vol 66 (1) ◽

pp. 97-104 ◽

Cited By ~ 10

Author(s):

Luis Enrique Cortés-Hernández ◽

Zahra Eslami-S ◽

Klaus Pantel ◽

Catherine Alix-Panabières

Keyword(s):

Tumor Cells ◽

Circulating Tumor Cells ◽

Liquid Biopsy ◽

Functional Characterization ◽

Clinical Information ◽

In Vivo Models ◽

Functional Studies

Abstract BACKGROUND One of the objectives for the liquid biopsy is to become a surrogate to tissue biopsies in diagnosis of cancer as a minimally invasive method, with clinical utility in real-time follow-ups of patients. To achieve this goal, it is still necessary to achieve a better understanding of the mechanisms of cancer and the biological principles that govern its behavior, particularly with regard to circulating tumor cells (CTCs). CONTENT The isolation, enumeration, detection, and characterization of CTCs have already proven to provide relevant clinical information about patient prognosis and treatment prediction. Moreover, CTCs can be analyzed at the genome, proteome, transcriptome, and secretome levels and can also be used for functional studies in in vitro and in vivo models. These features, taken together, have made CTCs a very valuable biosource. SUMMARY To further advance the field and discover new clinical applications for CTCs, several studies have been performed to learn more about these cells and better understand the biology of metastasis. In this review, we describe the recent literature on the topic of liquid biopsy with particular focus on the biology of CTCs.

Download Full-text

P28-Fur-Grb, A Novel Fusion Protein with Enhanced Targeted Cytotoxicity Against Breast Cancer

Clinical Oncology and Research ◽

10.31487/j.cor.2019.05.02 ◽

2019 ◽

pp. 1-8

Author(s):

Saeed Ranjbar ◽

Aria Momeni ◽

Azadeh Reshadmanesh ◽

Azita Fakhravar ◽

Nafiseh Paydarnia ◽

...

Keyword(s):

Breast Cancer ◽

Fusion Protein ◽

Tumor Cells ◽

Breast Cancer Cell Lines ◽

Target Cells ◽

Proliferative Potential ◽

Furin Cleavage ◽

Ic50 Values

Targeting tumor cells via multiple pathways promises the emergence of a new era in cancer therapy. Consisting of a cell-binding ligand and a cytotoxic moiety, cytolytic fusion proteins can selectively bind and kill target cells with minimal adverse effects. We designed a novel immunoproapoptotic fusion protein, p28-fur-GrB, composed of the cancer-specific azurin-derived cell penetrating peptide, p28, and a mutant version of human serine protease granzyme B. The two moieties were genetically fused by a furin sensitive linker, allowing in vivo cleavage and activation of the immunotoxin after cell entry. Synthesized coding gene of the recombinant protein was cloned and expressed in HEK293T cells, and nickel chromatography was applied for protein purification. After in vitro furin cleavage and primary analyses of SDS-PAGE, Western blotting, GrB activity and ELISA binding assay, the fusion protein was tested for its cytotoxicity on various breast cancer cell lines. Suppression of cell proliferation and viability was evaluated using the WST-1 assay. Furthermore, DNA fragmentation was measured as an indication of apoptotic effects of the fusion protein on treated cells. Based on our results, p28-fur-GrB was efficiently cleaved by furin and showed high GrB activity and binding affinity after cleavage. Following 72h of incubation with IC50 values of the fusion protein, significant cytotoxic effects of 80.6%, 77.1%, 74% and 69.6% were recorded for BT474, MCF7, SK-BR-3 and MDA-MB-231 tumor cells, respectively. Proliferative potential of MCF 10A normal cells was not affected by the treatment. Analysis of the rate of apoptosis in treated cells confirmed our cytotoxicity results. We concluded that p28-fur-GrB is a potent anti-tumor agent with high cytotoxicity against breast cancer cells.

Download Full-text